These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15253941)

  • 1. Will oral antithrombin agents replace warfarin?
    Sinnaeve PR; Van de Werf FJ
    Heart; 2004 Aug; 90(8):827-8. PubMed ID: 15253941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists.
    Wolzt M; Eriksson UG; Gouya G; Leuchten N; Kapiotis S; Elg M; Schützer KM; Zetterstrand S; Holmberg M; Wåhlander K
    Thromb Res; 2012 Apr; 129(4):e83-91. PubMed ID: 21925716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H; Selçuk MT; Maden O
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era..
    Mohapatra R; Tran M; Gore JM; Spencer FA
    Am Heart J; 2005 Jul; 150(1):19-26. PubMed ID: 16084146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
    Diener HC;
    Cerebrovasc Dis; 2006; 21(4):279-93. PubMed ID: 16449807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New possibilities in anticoagulant management of atrial fibrillation.
    Waldo AL
    Rev Cardiovasc Med; 2004; 5 Suppl 5():S30-8. PubMed ID: 15619613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
    Tangelder MJ; Frison L; Weaver D; Wilcox RG; Bylock A; Emanuelsson H; Held P; Oldgren J
    Am Heart J; 2008 Feb; 155(2):382-7. PubMed ID: 18215612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
    Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J
    Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential for changing prescribing patterns from warfarin to oral direct thrombin inhibitors: clinical scenarios.
    Reiffel JA
    Rev Cardiovasc Med; 2004; 5 Suppl 5():S12-21. PubMed ID: 15619610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ximelagatran, an oral thrombin inhibitor without the need for regular monitoring of the anticoagulant status].
    Tieleman RG
    Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2046-8. PubMed ID: 14606349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dietary implications for patients receiving long-term oral anticoagulation therapy for treatment and prevention of thromboembolic disease.
    Kampouraki E; Kamali F
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):789-797. PubMed ID: 28635328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran.
    Harenberg J; Ingrid J; Tivadar F
    Isr Med Assoc J; 2002 Nov; 4(11):1003-5. PubMed ID: 12489490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation.
    Katira R; Chauhan A; More RS
    Postgrad Med J; 2005 Jun; 81(956):370-5. PubMed ID: 15937202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ximelagatran: a promising new drug for oral anticoagulation].
    Scardi S; Giansante C
    Monaldi Arch Chest Dis; 2004 Mar; 62(1):34-9. PubMed ID: 15211735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ximelagatran: a new oral anticoagulant.
    Hrebickova L; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(6):397-408. PubMed ID: 14633322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orally active direct thrombin inhibitors.
    Weitz J
    Semin Vasc Med; 2003 May; 3(2):131-8. PubMed ID: 15199476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
    Konishi N; Hiroe K; Kawamura M
    Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ximelagatran: a new type of oral anticoagulant.
    Kwok L; Molckovsky D; Boucher M
    Int J Technol Assess Health Care; 2005; 21(4):480-6. PubMed ID: 16262971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Will direct oral anticoagulants completely replace warfarin?
    Thachil J
    Br J Hosp Med (Lond); 2018 Nov; 79(11):604-605. PubMed ID: 30418820
    [No Abstract]   [Full Text] [Related]  

  • 20. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
    Albers GW;
    Am J Manag Care; 2004 Dec; 10(14 Suppl):S462-9; discussion S469-73. PubMed ID: 15696910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.